Skip to main content
Alexander M. Lesokhin on Muck Rack

Alexander M. Lesokhin

As seen in: Nature, Wiley Online Library, JAMA Oncology, Cell Press, The Lancet, HemOnc Today, ONCOLOGY journal, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alexander M.

Contact Alexander M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients

|
By Ross Firestone, Anish K. Simhal, Jung Hun Oh, Kylee H. Maclachlan, Juan-Jose Garcés, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Neha Korde, Carlyn Tan, Sridevi Rajeeve, Hamza Hashmi, Alexander M. Lesokhin, Kinga Hosszu, Francesco Maura, Joseph Deasy, Saad Usmani, Malin Hultcrantz, Theresia Akhlaghi, Devin McAvoy
| Nature Verified
To the Editor: Smoldering multiple myeloma (SMM) is a precursor to active multiple myeloma (MM) characterized by a higher plasma cell burden than monoclonal gammopathy of undetermined significance (MGUS) but without evidence of the end-organ damage that defines MM [1, 2]. Current SMM guidelines advocate for close observation for progression to symptomatic progression to MM, with some studies suggesting the benefit of early intervention for patients with a high risk (HR) of progression [3].
Open in Who Shared Issue with article?

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

|
By Hamza Hashmi, Tara M. Sebastian, Sridevi Rajeeve, Ross Firestone, Eric Jurgens, Kevin Miller, Francesco Maura, Alexander M. Lesokhin, Carlyn Tan, Gunjan L. Shah, Neha Korde, Heather Landau, Michael Scordo, Hani Hassoun, Kylee H. Maclachlan, Urvi A. Shah, Malin Hultcrantz, Andriy Derkach, David Nemirovsky, Sergio A. Giralt, Sham Mailankody, Saad Usmani, Tasmin Farzana, Maximillian Merz
| Nature Verified
Abstract While CAR T has shown superior efficacy in earlier line of therapy [1, 2] for functionally high-risk multiple myeloma (FHRMM), outcomes with its use in later lines (3+) for FHR disease remain unknown. We describe a single-center experience of FHRMM patients (pts), defined as those with progression of disease (POD) < 24 months of frontline therapy, receiving CAR T-cell therapy.
Open in Who Shared Issue with article?

Dietary patterns among individuals with plasma cell disorders– opportunities for targeted interventions

|
By Kadiatou Traoré, Francesca Lo Castro, Andriy Derkach, Elan Gorshein, Edith Serrano, Alankrita Taneja, Alexander M. Lesokhin, Saad Usmani, Jay Hydren, Cynthia A Thomson, Urvi A. Shah, Jenifer M. Ahlstrom, Torin Block
| Nature Verified
Introduction Plasma cell disorders (PCDs) are a spectrum of diseases characterized by abnormal proliferation of plasma cells, from precursor conditions, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), to malignant multiple myeloma (MM). Over the past decade, therapeutic advances have improved survival and outcomes for MM patients.
Open in Who Shared Issue with article?
See all 16 licensed articles (18 Total)